Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (June 2022)
20 slides from Moleculin Biotech's investor presentation, Jun 9, 2022
Slide 1: Spmoncuum
Spmoncuum We:
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial positon, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,”
Slide 3: Investment Highlights
Investment Highlights Second Lead Program 1 study for treatment Pipeline Expansion additional h Global Network Leveraging network of preeminent global collaborators
Slide 4: Priority Development Pipeline
Priority Development Pipeline PROGRAM INDICATION Soft Tissue Sarcoma Lung Mets Annamycin —_. ‘Announced reaching RP20 and preliminary cfcacy data: pivoting to com! Acute Myeloid Leukemia Allowance to Pr Siva: hase iminary results from Phase 13 tril ‘expected H1 2022 which potentially assists future
Slide 5: Management Team with Proven Executional Expertise
Management Team with Proven Executional Expertise
Slide 6: Leveraging the Brightest Scientific Minds
Leveraging the Brightest Scientific Minds + HEMATOLOGY VIROLOGY ; be, Phi Marty Tallman, MD @ se soe | Am PANCREATI Bmovecuuin yy 6
Slide 7: Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications
Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications Clinical Highlights Target Indications: Announced RP2D and preliminary efficacy of 60% ORR in last cohort of single agent AML tri bo AML trial, expected to start H1 2022 Soft Tissue 130,000 cases worldwide? Sarcom
Slide 8: Annamycin: Next Generation Anthracycline
Annamycin Next Generation Anthracycline % of Mice with Heart Lesions Demonstrated to Be Non-Cardiotoxict : he Ability to overcome multi-drug resistance >30x greater accumulation in lungs than doxorubicin Potent topoisomerase-II poison with a wider en therapeutic window than doxorubicin? <10% inciden
Slide 9: Annamycin: Ongoing Phase 1b/2 Study for STS Lung Mets
Annamycin Ongoing Phase 1b/2 Study for Treatment of STS Lung Mets US Multi-Center, Open-Label, Dose Escalation Study eaneilse ouils Primary Endpoint Planned Phase 2 establish MTD/RP2D expansion (25 patients) will and safety evaluate efficacy Promising Early Clinical Activity in Phase 1b! Bmovecuuin
Slide 10: Annamycin: STS Clinical Benefit to Date
Annamycin STS: Clinical Benefit to Date’ 9 44% patients treated (3 of 5 cohorts completed) of patients in first 3 cohorts experienced preliminary clinical activity, defined as stable disease and/or better 100% dose-limiting toxicity (DLT) experienced to-date No cardiotoxicity has been shown in subje
Slide 11: Ongoing Phase 1/2 Study for Treatment of Relapsed or Refractory AML
Ongoing Phase 1/2 Study for Treatment of Relapsed or Refractory (R/R) AML Poland Multi-Center, Open-Label, Dose Escalation Study 240 Ang hae 1, 2& 3 with 21 days off Preclinical data Pr eu Infusion days ytarabine (Anr Primary Endpoint Planned Phase 1/2 establish safety and AnnAraC with 190 mg/m? ini
Slide 12: Annamycin: AML Clinical Benefit to Date
Annamycin AML Clinical Benefit to Date’ patients taken above the lifetime 12 maximum anthracycline dose established by FDA No cardiotoxicity has been 100% _ shown in subjects treated to date in Moleculin’s clinical trials 79 R/R AML patients? treated in . = both US and EU trials preliminary overall
Slide 13: The Full Annamycin Opportunity
The Full Annamycin Opportunity Potential for Significant Upside = 6 TNBC Lung, Pancreatic Liver — 67k RecLure 67K — 13,500 STSLurg Mets Endometrial Lung Initial Annamycin 104k Target Indications Colorectal re Potential Annamycin Sp TOTALINCIDENCE Expansion Indications ~33.5K TOTAL INCIDENCE para ; ~
Slide 14: WP1122: Phase 1 Study for COVID-19 Also Accelerates Oncology Program
WP1122: Phase 1 Study for COVID-19 Also Accelerates Oncology Program sf y f Key Highlights F, - Prodrug of glucose decoy enables drug-like properties Targets glycolysis and glycosylation limits viral infectivity and replication Regulatory Highlights MHRA authorization tocommence Phase la Commenced p
Slide 15: WP1122: Treatment of COVID-19
P1122 Treatment of COVID-19 Multiple independent University studies show antiviral activity of 2-DG against SARS-CoV-2 2-DG has Emergency Use Authorization for treating COVID- 19 in India based on Phase 2 results? WP1122is a prodrug of 2-DG that has substantially higher in vitro antiviral activity t
Slide 16: Additional Development Pipeline
Additional Development Pipeline Additional Follow-on Opportunities Provide Potential for Significant Upside PROGRAM INDICATION PRECUNICAL PHASE PHASE? [UPCOMING MILESTONES, ‘Annamycin WP1056 + Radiation wp1220 wp1122 wP1122, WP1096, we1097
Slide 17: Financial Snapshot
Financial Snapshot Nasdaq: MBRX Strong Cash Position Funds Operations into 2024! ~28.6M Shares Outstanding* 95K 3 Month Avg. Volume? v
Slide 18: Targeted Value-Driving Milestones
Targeted Value-Driving Milestones 7 2021 2022 PROGRAM INDICATION 2 m1 "2 Annamycin S:MOLECULIN 18
Slide 19: Investment Summary
Investment Summary Lead Program, Annamycin ee mat dows 7 ry aca rule dvancing growing pipeline ity with data from Additional Pipeline ‘expansion oppor to fuel future grow! Leveraging Relationships with world-renowned organizations Sufficient Capital to Fund Operations into 2024! MOLECULIN 19
Slide 20: Thank You!
Thank You! od, og MOLECULIN Coy
Moleculin Biotech — Investor Presentation (June 2022) on 6ix